

Committed to Beating Inflammation



The inflammatory truth for millions

Rheumatoid Arthritis (RA), Ulcerative Colitis (UC) and Crohn's Disease (CD) currently affect around **5 million Europeans**.^{1,2,3}

Managing these conditions every single day **weighs heavily on each individual and their families**.

Despite so many people living with this burden,⁴ there's still a **real need for treatments**,^{5,6} which can transform lives from limited to liberated.



Working towards inflammation transformation

As a pioneering biotech company, we're dedicated to creating innovative medicines with one simple purpose: **to improve people's lives**.

We are **investing in treatment options for the long-term** and taking an inclusive approach to helping patients beyond treatment.

Guided by science, driven by challenge and relentless in our ambition, we work hard to push the limits of what's possible to help patients.



Collaborating to change lives

We know that we need the input and expertise of others, co-creating and collaborating to help us go further, faster and change **lives sooner**.

That's why we've **formed partnerships in inflammation** with healthcare professionals, research institutions, academia, scientists, discovery partners, patients and patient organisations to help individuals most in need get access to our medicines and our science.

The Galapagos difference

Our commitment to inflammation goes back over 20 years to our beginnings as a pioneering target discovery company.

Exploring the unknown and daring to take risks is part of our DNA, and this fearless mindset coupled with our specific focus gives us the agility to take decisions faster and drive positive change for the patients we serve.

We are committed to beating inflammation, and as long as we can change people's lives for the better, we will not cease being part of the solution.



To learn more about how we are working towards our commitment to inflammation, please visit our website: www.glp.com/inflammation.

References

1. Burisch J, Jess T, Martinato M, Lakatos PL; ECCO-EpiCom. The burden of inflammatory bowel disease in Europe. *J Crohns Colitis*. 2013 May; 7(4):322-37.
2. Galloway J, Capron JP, De Leonardis F, et al. The impact of disease severity and duration on cost, early retirement and ability to work in rheumatoid arthritis in Europe: an economic modelling study. *Rheumatol Adv Pract*. 2020;4(2):rkaa041. Published 2020 Sep 16. doi:10.1093/rap/rkaa041.
3. GBD 2017 Inflammatory Bowel Disease Collaborators. Lancet The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. 2020; 5: 17-30.
4. Bullock J, Rizvi SAA, Saleh AM, et al. Rheumatoid Arthritis: A Brief Overview of the Treatment. *Med Princ Pract*. 2018;27(6):501-507.
5. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. *Bone Res*. 2018;6:15.
6. El-Gabalawy HD, Lipsky PE. Why do we not have a cure for rheumatoid arthritis? *Arthritis Res*. 2002;4 Suppl 3.